Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2073-2081

  Holzer, Timothy R ^a   Fulford, Angie D ^a   Arkins, Austin M ^a   Grondin, Janet M ^a   Mundy, Christopher W ^a   Nasir, Aejaz ^a   Schade, Andrew E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Biopsy; Immunohistochemistry; Ischemia; Phosphoproteins; Pre analytical variables; Xenografts

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CLINICAL DECISION MAKING; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 79960467037     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Coleman WB and Tsongalis GJ: Molecular mechanisms of human carcinogenesis. Experientia Supplementum 96: 321-349, 2006.
2. Moasser MM: Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26: 6577-6592, 2007.
3. Moasser MM: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469-6487, 2007.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004. (Pubitemid 39209661)
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
7. Barker PE: Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann N Y Acad Sci 983: 142-150, 2003.
8. Hinman LM, Huang SM, Hackett J, Koch WH, Love PY, Pennello G, Torres-Cabassa A and Webster C: The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop. Pharmacogenomics J 6: 375-380, 2006. (Pubitemid 44811532)
9. Torlakovic EE, Riddell R, Banerjee D, El-Zimaity H, Pilavdzic D, Dawe P, Magliocco A, Barnes P, Berendt R, Cook D, Gilks B, Williams G, Perez-Ordonez B, Wehrli B, Swanson PE, Otis CN, Nielsen S, Vyberg M and Butany J: Canadian Association of Pathologists-Association Canadienne des Pathologistes National Standards Committee/Immunohistochemistry: Best practice recommendations for standardization of immunohistochemistry tests. Am J Clin Pathol 133: 354-365, 2010.
10. Coleman R: The impact of histochemistry - a historical perspective. Acta Histochem 102: 5-14, 2000.
11. Mandell JW: Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem Cell Biol 130: 465-471, 2008.
12. Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP and Hsi ED: Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 31: 233-239, 2007. (Pubitemid 46175024)
13. Birle DC and Hedley DW: Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol Cancer Ther 5: 2494-2502, 2006. (Pubitemid 44650913)
14. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT and Nolan GP: Single-cell profiling of potentiated phosphoprotein networks in cancer cells. Cell 118: 217-228, 2004. (Pubitemid 38962577)
15. Kurosawa M: Phosphorylation and dephosphorylation of protein in regulating cellular function. J Pharmacol Toxicol Methods 31: 135-139, 1994.
16. Zuluaga Toro T, Hsieh FH, Bodo J, Dong HY and Hsi ED: Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation. Br J Haematol 139: 31-40, 2007. (Pubitemid 47389913)
17. Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF, 3rd and Liotta LA: Reverse-phase protein microarrays for monitoring biological responses. Methods Mol Biol 383: 321-336, 2007.
18. Brader S and Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90: 2-8, 2004. (Pubitemid 38541717)
19. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
20. Wymann MP and Marone R: Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 17: 141-149, 2005. (Pubitemid 40380937)
21. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
22. Bradham C and McClay DR: p38 MAPK in development and cancer. Cell Cycle 5: 824-828, 2006.
23. Espina V, Mueller C, Edmiston K, Sciro M, Petricoin EF and Liotta LA: Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl 3: 874-882, 2009.
24. Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM and Atkins MB: Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res 14: 3699-3705, 2008.
25. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C and Powis G: Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11: 4338-4340, 2005.
26. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D and Kulkarni S: Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22: 1457-1467, 2009.
27. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'Hern R, Nerurkar A, Osin P, Smith IE and Dowsett M: Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 12: R76, 2010.
28. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF, 3rd and Liotta LA: A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7: 1998-2018, 2008.
29. Bodo J, Durkin L and Hsi ED: Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology. J Histochem Cytochem 57: 701-708, 2009.
30. Obata T, Brown GE and Yaffe MB: MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 28: N67-77, 2000.
31. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, Vanderbilt C and Cobb MH: MAP kinases. Chem Rev 101: 2449-2476, 2001.
32. Mann GB, Fahey VD, Feleppa F and Buchanan MR: Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23: 5148-5154, 2005. (Pubitemid 46224023)